InvestMacro

Source: McAlinden Research  (9/6/23)

McAlinden Research shares a deep dive into a market driver with alpha-generating potential.

The FTC notes that, as part of the settlement, attorneys general from six states — California, Illinois, Minnesota, New York, Washington, and Wisconsin — will also dismiss a related federal court preliminary injunction action.

There was significant doubt cast upon the FTC’s case not long after the commission originally filed its suit in May, given its employment of a novel theory that Amgen could eventually bundle its drugs with those it is acquiring from Horizon in negotiations with insurers — therefore entrenching Horizon products’ premiere placement in the market and choking out potential competitors that might be cheaper or more effective. Horizon currently sells two marketed products, Tepezza (teprotumumab) for thyroid eye disease and Krystexxa (pegloticase), a chronic refractory gout treatment.

Since Amgen was quick to agree that they would not bundle their products with Horizon’s, a settlement was the natural conclusion. Further conditions of the agreement between the FTC and the two firms stipulate Amgen will not introduce discount or rebate schemes on their own products that would influence the sale or positioning of Horizon’s drugs.

The FTC, which has become more aggressive toward mega-mergers across multiple industries, presented the Amgen-Horizon settlement as a win, but it seems more likely that an ongoing wave of M&A activity among pharmaceutical and biotechnology firms will be bolstered by the sudden conclusion of the suit.

GlobalData’s Deals Database, cited by Pharmaceutical Technology, notes that there were 479 pharma M&A deals announced in Q2 2023, increasing by 18% QoQ in Q2 and 151% YoY. The total value of these deals was $51 billion, decreasing by -30% in Q2, compared with the previous quarter’s total of $72.5 billion. Still, Q2’s pharma industry M&A deal value rose by 77% YoY.

Though fewer deals were signed in the first quarter than in the second, the size of Q1’s deal value was boosted by Pfizer Inc.’s announcement that they would be acquiring massive biotech firm Seagen Inc. in biopharma’s largest deal in almost four years’ time. Pfizer’s offer of $229 per share in cash, a 33% premium on Seagen’s share price at the close preceding the deal becoming public, pushed the total value of the deal to $43 billion.

As MRP has previously noted, Pfizer executives have been among a consortium of biopharma heads that have voiced their desire to increase dealmaking with outside companies. Pfizer has set a goal of adding $25 billion in revenue by 2030 from business development moves, including acquisitions. Those could help the company offset an estimated drop of roughly $17 billion in sales from upcoming patent expirations. Bloomberg notes that Pfizer thinks that sales of Seagen’s four FDA-approved oncology products will exceed $10 billion, about $2 billion more than analysts’ estimates.

The smooth closure of the Pfizer-Seagen tie-up is still beholden to regulators at the FTC, but the recent news on the Amgen-Horizon deal is likely to invigorate confidence among investors that this deal will ultimately receive approval as well.

As of July, the FTC requested more information from Pfizer and Seagan in their review of the deal. Fierce Pharma writes that second requests from the FTC occur in roughly 25% of M&A deals, citing MEDACorp data. The regulator challenges such a transaction 5% — 10% of the time.

Charts

Important Disclosures:

1. Statements and opinions expressed are the opinions of the author and not of Streetwise Reports or its officers. The author is wholly responsible for the validity of the statements. The author was not paid by Streetwise Reports for this article. Streetwise Reports was not paid by the author to publish or syndicate this article. Streetwise Reports requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Streetwise Reports relies upon the authors to accurately provide this information and Streetwise Reports has no means of verifying its accuracy.
2. This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
3. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

McAlinden Research Partners Disclosures
This report has been prepared solely for informational purposes and is not an offer to buy/sell/endorse or a solicitation of an offer to buy/sell/endorse Interests or any other security or instrument or to participate in any trading or investment strategy. No representation or warranty (express or implied) is made or can be given with respect to the sequence, accuracy, completeness, or timeliness of the information in this Report. Unless otherwise noted, all information is sourced from public data.
McAlinden Research Partners is a division of Catalpa Capital Advisors, LLC (CCA), a Registered Investment Advisor. References to specific securities, asset classes and financial markets discussed herein are for illustrative purposes only and should not be interpreted as recommendations to purchase or sell such securities. CCA, MRP, employees and direct affiliates of the firm may or may not own any of the securities mentioned in the report at the time of publication.

Source: Adrian Day  (9/6/23)

Global Analyst Adrian Day looks at two of his favorite companies, both of which have royalties on the same asset. 

Altius Minerals Corp. (ALS:TSX.V) reported second-quarter earnings lower than analyst expectations, largely due to higher depreciation and stock compensation, as well as lower earnings from the renewables unit. Royalty revenues, which had been pre-announced (see Bulletin #873), were lower largely due to the closure of the 777 Mine as well as the lower commodities prices, including potash, which spiked at the onset of the Russia-Ukraine war.

These factors will also weigh on full-year revenues compared with last. Altius has a good financial position, ending the quarter with almost $25 million in cash (excluding $54 million held at majority-held Altius Renewables) and $117 million in debt. It has about $94 million still available on its revolver. The company holds equity interests of almost $400, including $173 million in Altius Renewable and $116 million in Labrador Iron Ore Royalty Corp., neither of which is, however, viewed as a short-term source of cash.

Its portfolio of prospect generators is valued at $42 million. Together with other shares, the total share portfolio stands at a total of C$387 million. In addition to scheduled debt repayments of $2 million during the quarter, the company also spent another $2.1 million buying back 98 million shares. It has recently renewed its share repurchase program, allowing it to buy up to 4.21% of shares outstanding over the next 12 months. Altius said that the value of Altius is “from time to time” greater than the market price of the shares. The company has had an active buy-back program since 2010.

Some Projects Pushed Back

On the project front, there were some setbacks, but for the most part, postponements of expansions and nothing that will affect near-term revenues. The major exception is the long-anticipated closure of the Genesee coal operations in Alberta (but see below). Altius has no other current source of revenue that is running down or nearing its end of life.

Other than that, there have been some delays in future projects. Nutrien announced the suspension of plans to expand its potash output, on which Altius has a royalty, though this is likely to be temporary, and will not affect near-term revenues. In addition, a planned expansion at the Chapada copper mine has been delayed, though several expansion opportunities are being evaluated by miner Lundin, following positive results at the Sauva discovery there, and the Chapada mine continues to generate royalty revenue for Altius.

In many ways, these delays are for positive reasons. On the other hand, there are projects that are growing and can reasonably be expected to generate significant long-term revenues for Altius. What it calls its “option value realization progress” is well underway, and several projects that Altius discovered are approaching production.

Exposure To World-Class Gold Camp

Most notably, AngloGold Ashanti Ltd. (AU:NYSE; ANG:JSE; AGG:ASX; AGD:LSE) provided resource estimates for its Merlin deposit, adjacent to Silicon, in southern Nevada, over which Altius holds a 1.5% royalty. Anglo has an “exploration target,” similar to a resource estimate, of 6-8 million ounces at Merlin, in addition to 4.2 million at Silicon, making this an emerging world-class asset, with the advantages of being in a strong jurisdiction with a major operator. (See Bulletin #875 for report on Orogen, which also holds a royalty on these deposits.)

The deposits remain open, Merlin in three directions and at depth, so the potential for the resource to grow further is very strong. Altius also believes its royalty extends to the whole area of adjacent claims, though this is disputed by Anglo and is the subject of arbitration set for April. Add the entire area together, and 20 million ounces is within sight, with several areas not yet properly drilled.

Potentially, this could be a 500,000-a-year producer for 30 years. If Altius’ claim is upheld, not only would it have a royalty over many more ounces, but those ounces would start generating revenue sooner.

How Much Is It Worth?

A reasonable valuation on just the royalty that is not disputed could be north of $150 million, representing about 15% of Altius’ NAV. (Other analysts value the royalty variously at $64 million, another at $75 million, but I believe these lowest are grossly undervaluing the asset, while others are meaningfully higher. Given the top location as well as the major operator, a premium is justified.) Although part of the project (North Bullfrog) is expected to start production in 2025, Silicon and Merlin — which may yet be one large pit — are not expected to commence operations until 2028 or 2029, though no firm mine plan has been announced.

Altius has not yet decided how to maximize the value of this asset. It has looked at swapping the royalty for non-gold royalties — since gold royalties are generally valued higher, Altius could exchange for great future cash flow in non-gold royalties — but finding royalties of comparable quality and value has proved challenging especially as the project has grown. It has also considered putting its royalty together with Orogen’s royalty on Silicon and Merlin in some fashion, in the belief that a combined royalty would be more valuable to an acquirer.

Altius is the largest shareholder in Orogen, with 15% of the shares plus warrants. It is known that general discussions have taken place, but nothing definitive has come out of them. In all likelihood, nothing will happen on any front until Anglo releases what it calls a “concept study,” similar to a PEA, scheduled for year-end, and Altius’ arbitration has been decided.

It is now possible that the company may simply decide to hold on to the royalty for the tremendous, long-life cash flow it will provide.

An Iron Ore Deposit Advances

Altius also has another very significant project moving towards production, the Kami iron ore deposit, over which Altius holds a 3% royalty, now owned by Champion. The miner is planning to announce an updated feasibility study by year-end. Kami is very high-quality iron ore, making it potentially attractive to major companies with lower-quality ore for blending to meet European standards.

Although Champion is unlikely to want to sell the project, it could seek project financing from a major in return for offtake agreements. Kami might be four years away from production, but that could be up to $50 million a year fully ramped up (likely to be $25 million/year in the first stage but double that after a couple of years.) On the forced closure of the Genesee coal royalty, Altius has a lawsuit against the government of Alberta.

Although it lost the lower court case, a subsequent Supreme Court ruling in an unrelated but similar case gives ground for some optimism when Altius’ appeal is heard, expected in the fall. Altius also sees a path from existing projects to increase revenues at 57% owned Altius Renewable Royalties to as much as $17 million in attributable revenues within three years. There are many other assets within the Altius portfolio, both cash-generating and nonproducing, that we have not touched on here. Some others, such as Voisey’s Bay nickel mine, have the potential to surprise with their upside beyond existing mine lifes.

People’s Most Important Asset

Altius is a core holding, offering exposure, mostly through royalties, to a broad range of commodities, from copper and nickel to phosphate and renewables. Although it does buy royalties, it has also generated many royalties through its own exploration efforts. The Altius model involves finding partners to carry forward projects it finds, but it does this usually by creating a new company retaining both shares and royalties.

When the company eventually goes public, Altius sells down its share positions, keeping the royalties. There is a broad range of royalties on long-life assets, with several offering meaningful upside in coming years, a solid balance sheet, and above all, a group of some of the smartest people in the industry. Led by co-founder and CEO Brian Dalton, they include chief geologist Lawrence Winter, VP of project generation Chad Wells, and chairman and co-founder John Baker.

The first three were at university together. Dalton not only understands the cyclical nature of the sector, but he also has the patience and discipline to act in a counter-cyclical manner. He has the imagination to think outside of the box and see opportunities that others miss. I could similarly sing high the praises of other members of the team — Lawrence is as keen a geologist as I have met, while Chad’s returns managing the prospect generator portfolio put most money managers to shame.

The very high-quality board includes, inter alia, our old friend from Virginia Gold, Andre Gaumond, who possesses a range of experience and independent thinking. I like to get to know the top management of companies in which we invest, and in the case of Altius, the more one knows them, the more one comes to respect them. No wonder Altius is a core holding for us and one that has several opportunities to meaningfully increase and, in combination, well more than double revenues in the coming years.

If you do not already own, you should buy and use any pullbacks to add to positions.

Orogen Has Solid Cash Flow and Upside From Silicon

Orogen Royalties Inc. (OGN:TSX.V) announced another profitable quarter, underpinned by increased revenue from its royalty at Ermitaño. New milling equipment at First Majestic’s Santa Elena mine has increased recovery rates to record levels; most of the ore going to the mill is now coming from Ermitaño.

Overall royalty income of $1.2 million was up 25% from the same quarter a year ago, though down 10% sequentially. Production at Ermitaño is expected to increase in the second half by 27%. Significantly, too, recent drilling has shown the potential for reserve replacement, with strong results from central Ermitaño but also good results to the east.

Orogen also holds royalties on the adjacent Ermitaño East and Cumobabi deposits. The company has reduced its G&A expenses by 36% compared with the previous quarter. The company, debt-free, has working capital of CA$16.8 million, up $4.7 million from the previous quarter. On the current mine plan, Orogen will receive royalty revenue through 2027, but we expect the mine to last beyond 2027 as Ermitaño East and Cumobabi are more fully explored. At any rate, this revenue should continue until the Silicon royalty kicks in. In total, over 100,000 meters of drilling is estimated on Orogen’s royalty ground in 2023. Most of the 24 projects on which it holds royalties were generated through the prospect generator business.

One Asset Worth More Than Current Value

Orogen holds a 1% royalty on the Silicon and most of the Merlin deposit. Altius holds a 1.5% royalty on these two deposits (though with slightly different boundaries) as well as the disputed claim over the larger district. We would value Orogen’s royalty at US$100 million, and one that will likely grow. Again, though some analysts put the value considerably less, one respected analyst puts the value at $150 million to $180 million. We don’t calculate that it’s there quite yet, but we could easily get there with more drilling.

If we take $100 million to be conservative, plus $40 million for Ermitano, another $18 million for the project generation business (a competitor’s estimate of the value), and $12 million in cash and shares, you get on a sum-of-the-parts basis to US$170 million on a very reasonable basis. The current market cap is less than US$90 million, providing an enormous gap between share price and value. Again, as discussed previously (see Bulletin #875), Orogen has current cash flow, a world-class royalty, an active prospect generator portfolio, well executed, plenty of cash, and solid management.

Although it is a small-cap company — currently CA$120 million — it is a stock that belongs in all portfolios; size does not determine quality!

Orogen is a Strong Buy at this level.

TOP BUYS this week, in addition to above, include Osisko Gold Royalties Ltd. (OR:TSX; OR:NYSE), Barrick Gold Corp. (ABX:TSX; GOLD:NYSE), Agnico Eagle Mines Ltd. (AEM:TSX; AEM:NYSE), Fortuna Silver Mines Inc. (FSM:NYSE; FVI:TSX; FVI:BVL; F4S:FSE), Midland Exploration Inc. (MD:TSX.V), Lara Exploration Ltd. (LRA:TSX.V), and Hutchison Port Holdings Trust (HPHT:Singapore).

QUESTIONS FROM READERS

After reading your report on Pan American Silver, it’s hard to believe that it is losing money again. MS

Pan American Silver Corp.’s (PAAS:TSX; PAAS:NASDAQ) recent quarterly loss was the result largely of expenses related to its acquisition earlier this year of Yamana, including a one-time accounting loss on the sale of the Morococha mine. Excluding these special expenses, Pan American had a profitable quarter. Perhaps I was not clear enough.

I like Pan American here.

UPCOMING APPEARANCES Next Saturday, the 9th, I’ll be speaking at the always-stimulating Capitalism & Morality Conference in Vancouver. If you are in town, it’s well worth attending. See the program and registration details here.

November, 1st to 4th, is the annual New Orleans Investment Conference. Always educational, challenging, and fun, it is a must-event on my annual calendar. Speakers, too many to list, include Peter Boockvar, a walking almanac of all things economic; Robert Prechter, George Gammon, and the always-controversial Prof. Dave Collum. Details can be found here.

Important Disclosures:

1. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Altius Minerals Corp., Orogen Royalties Inc., Osisko Gold Royalties Ltd., Barrick Gold Corp., Agnico Eagle Mines Ltd., Fortuna Silver Mines Inc., Midland Exploration Inc., Lara Exploration Ltd., and Pan American Silver Corp.
2. Adrian Day: I, or members of my immediate household or family, own securities of: All. My company has a financial relationship with: All. I determined which companies would be included in this article based on my research and understanding of the sector.
3. Statements and opinions expressed are the opinions of the author and not of Streetwise Reports or its officers. The author is wholly responsible for the validity of the statements. The author was not paid by Streetwise Reports for this article. Streetwise Reports was not paid by the author to publish or syndicate this article. Streetwise Reports requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Streetwise Reports relies upon the authors to accurately provide this information and Streetwise Reports has no means of verifying its accuracy.
4.  This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.

For additional disclosures, please click here.

Adrian Day Disclosures

Adrian Day’s Global Analyst is distributed for $990 per year by Investment Consultants International, Ltd., P.O. Box 6644, Annapolis, MD 21401. (410) 224-8885. www.AdrianDayGlobalAnalyst.com. Publisher: Adrian Day. Owner: Investment Consultants International, Ltd. Staff may have positions in securities discussed herein. Adrian Day is also President of Global Strategic Management (GSM), a registered investment advisor, and a separate company from this service. In his capacity as GSM president, Adrian Day may be buying or selling for clients securities recommended herein concurrently, before or after recommendations herein, and may be acting for clients in a manner contrary to recommendations herein. This is not a solicitation for GSM. Views herein are the editor’s opinion and not fact. All information is believed to be correct, but its accuracy cannot be guaranteed. The owner and editor are not responsible for errors and omissions. © 2023. Adrian Day’s Global Analyst. Information and advice herein are intended purely for the subscriber’s own account. Under no circumstances may any part of a Global Analyst e-mail be copied or distributed without prior written permission of the editor. Given the nature of this service, we will pursue any violations aggressively.